

Ming-Wen An

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1947313/publications.pdf>

Version: 2024-02-01

16
papers

275
citations

1307366

7
h-index

996849

15
g-index

16
all docs

16
docs citations

16
times ranked

472
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical trial designs incorporating predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2016, 43, 74-82.	3.4	61
2	Precision oncology: A new era of cancer clinical trials. <i>Cancer Letters</i> , 2017, 387, 121-126.	3.2	53
3	Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse. <i>Journal of Clinical Oncology</i> , 2014, 32, 841-850.	0.8	40
4	Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials. <i>Clinical Cancer Research</i> , 2011, 17, 6592-6599.	3.2	27
5	Test on existence of histology subtype-specific prognostic signatures among early stage lung adenocarcinoma and squamous cell carcinoma patients using a Cox-model based filter. <i>Biology Direct</i> , 2015, 10, 15.	1.9	25
6	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv239.	3.0	18
7	A 2-Stage Phase II Design with Direct Assignment Option in Stage II for Initial Marker Validation. <i>Clinical Cancer Research</i> , 2012, 18, 4225-4233.	3.2	17
8	A Stochastic Simulator of a Blood Product Donation Environment with Demand Spikes and Supply Shocks. <i>PLoS ONE</i> , 2011, 6, e21752.	1.1	7
9	Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. <i>Journal of Clinical Oncology</i> , 2015, 33, 4048-4057.	0.8	6
10	Principles of Good Clinical Trial Design. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1277-1280.	0.5	6
11	Choosing profile double-sampling designs for survival estimation with application to President's Emergency Plan for AIDS Relief evaluation. <i>Statistics in Medicine</i> , 2014, 33, 2017-2029.	0.8	5
12	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100492.	0.5	5
13	Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. <i>Contemporary Clinical Trials</i> , 2014, 38, 157-162.	0.8	2
14	The Direct Assignment Option as a Modular Design Component: An Example for the Setting of Two Predefined Subgroups. <i>Computational and Mathematical Methods in Medicine</i> , 2015, 2015, 1-6.	0.7	2
15	Time to progression ratio: promising new metric or just another metric?. <i>Annals of Translational Medicine</i> , 2016, 4, S43-S43.	0.7	1
16	Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2021, 23, 100827.	0.5	0